![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF611 |
Gene summary for ZNF611 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF611 | Gene ID | 81856 |
Gene name | zinc finger protein 611 | |
Gene Alias | ZNF611 | |
Cytomap | 19q13.41 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8N823 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
81856 | ZNF611 | RNA-P17T-P17T-2 | Human | Lung | IAC | 4.46e-03 | 7.83e-01 | 0.3371 |
81856 | ZNF611 | RNA-P17T-P17T-8 | Human | Lung | IAC | 9.91e-03 | 6.41e-01 | 0.3329 |
81856 | ZNF611 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 1.48e-08 | 4.01e-01 | -0.0166 |
81856 | ZNF611 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 2.74e-06 | 3.24e-01 | -0.0132 |
81856 | ZNF611 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 1.42e-06 | 3.14e-01 | -0.013 |
81856 | ZNF611 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 3.13e-06 | 3.60e-01 | -0.0121 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Lung | ![]() | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF611 | SNV | Missense_Mutation | c.1484C>T | p.Ser495Leu | p.S495L | Q8N823 | protein_coding | deleterious(0.04) | benign(0.259) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD | |
ZNF611 | SNV | Missense_Mutation | novel | c.871N>C | p.Glu291Gln | p.E291Q | Q8N823 | protein_coding | deleterious(0.03) | probably_damaging(0.947) | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ZNF611 | SNV | Missense_Mutation | c.1018G>C | p.Glu340Gln | p.E340Q | Q8N823 | protein_coding | deleterious(0.02) | probably_damaging(0.926) | TCGA-C8-A12Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
ZNF611 | SNV | Missense_Mutation | c.1678C>G | p.His560Asp | p.H560D | Q8N823 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A1AZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
ZNF611 | SNV | Missense_Mutation | rs763630284 | c.490N>G | p.Leu164Val | p.L164V | Q8N823 | protein_coding | tolerated(0.06) | possibly_damaging(0.893) | TCGA-EW-A1OZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD |
ZNF611 | SNV | Missense_Mutation | novel | c.796N>C | p.Lys266Gln | p.K266Q | Q8N823 | protein_coding | deleterious(0.01) | probably_damaging(0.98) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZNF611 | SNV | Missense_Mutation | novel | c.871N>A | p.Glu291Lys | p.E291K | Q8N823 | protein_coding | deleterious(0.04) | possibly_damaging(0.541) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
ZNF611 | SNV | Missense_Mutation | rs751448997 | c.374T>A | p.Leu125His | p.L125H | Q8N823 | protein_coding | tolerated(0.59) | benign(0) | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
ZNF611 | SNV | Missense_Mutation | novel | c.319G>C | p.Glu107Gln | p.E107Q | Q8N823 | protein_coding | tolerated(1) | benign(0.022) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF611 | SNV | Missense_Mutation | rs539472475 | c.530G>C | p.Gly177Ala | p.G177A | Q8N823 | protein_coding | tolerated(0.5) | benign(0.005) | TCGA-VS-A9UL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |